Evidence map›Paper›PMID 30844679›Full record

ArticleCancer epidemiology2019

The impact of rheumatological disorders on lymphomas and myeloma: a report on risk and survival from the UK's population-based Haematological Malignancy Research Network.

Eleanor Kane, Daniel Painter, Alexandra Smith, Simon Crouch, Steven Oliver, Russell Patmore, Eve Roman

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer epidemiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Eleanor KaneDepartment of Health Sciences, University of York, York, UK. Electronic address: eleanor.kane@york.ac.uk.
Daniel PainterDepartment of Health Sciences, University of York, York, UK.
Alexandra SmithDepartment of Health Sciences, University of York, York, UK.
Simon CrouchDepartment of Health Sciences, University of York, York, UK.
Steven OliverDepartment of Health Sciences, University of York, York, UK; Hull York Medical School, York, UK.
Russell PatmoreQueens Centre for Oncology, Castle Hill Hospital, Hull, UK.
Eve RomanDepartment of Health Sciences, University of York, York, UK.
University of York · GBCastle Hill Hospital · GB

Funding

Cancer Research UK C9474/A18362
6 · The paper itself

Abstract

backgroundAutoimmune inflammatory disease increases the risk of diffuse large B-cell lymphoma (DLBCL) and marginal zone lymphoma (MZL), but findings for other mature B-cell malignancies are equivocal. Furthermore, it has been suggested that the increase in DLBCL is due to the activated B-cell (ABC) subtype; but data on this, and the impact of inflammatory co-morbidities on survival, are sparse and contradictory.

methodsData are from an established UK population-based cohort. Patients (n = 6834) diagnosed between 01/2009 and 08/2015 are included; DLBCL (n = 1771), myeloma (n = 1760), chronic lymphocytic leukaemia (CLL, n = 1580), MZL (n = 936), and follicular lymphoma (FL, n = 787). Information on rheumatological disorders and deaths was obtained by record-linkage to nationally compiled Hospital Episode Statistics, with age-and sex-matched individuals (n = 68,340) from the same catchment population (˜4 million people) providing the comparator.

resultsSignificantly increased risks for DLBCL (OR = 2.3, 95% CI 1.8-2.8) and MZL (OR = 2.0, 95% CI 1.5-2.7) were found for those with rheumatological disorders; the site distribution of those with/without rheumatological conditions differing for DLBCL (p = 0.007) and MZL (p = 0.002). No increases in risk were observed for the remaining mature B-cell malignancies, and no associations with survival were detected for DLBCL (age-adjusted HR = 1.2, 95% CI 0.9-1.6) or MZL (age-adjusted HR = 1.0, 95% CI 0.6-1.9). Furthermore, whilst our findings provide evidence for an association with rheumatological disease severity for DLBCL, they offer little support for the notion that the association is driven by an increase in the incidence of the ABC subtype.

conclusionOur findings support the hypothesis that the chronic activation and proliferation of specific B-cell populations which characterize autoimmune disease increase the potential for the lymphomagenic events that lead to DLBCL and MZL in both males and females; but have no impact on the development of CLL, FL or MM, or on survival.

Indexed as

AgedAged, 80 and overFemaleHumansLeukemia, Lymphocytic, Chronic, B-CellLymphomaLymphoma, B-Cell, Marginal ZoneLymphoma, FollicularLymphoma, Large B-Cell, DiffuseMaleMiddle AgedMultiple MyelomaRheumatic DiseasesUnited KingdomAutoimmune diseaseChronic lymphocytic leukaemiaDiffuse large B-cell lymphomaFollicular lymphomaMarginal zone lymphomaMultiple myelomaRheumatoid arthritis

Identifiers

PMID30844679
PMCPMC6452783
OpenAlexW2920650940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.